SCHEMBL3079922

SCHEMBL3079922

COCNC(=O)c1cc(C)nc(NC(C)C)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
MAPK1 P28482 1/20 0.39
GRM5 P41594 2/20 0.36
CYP2C9 P11712 1/20 0.36
MAPT P10636 3/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
RECQL P46063 1/20 0.35
KMT2A Q03164 1/20 0.35
POLB P06746 1/20 0.35
RAB9A P51151 1/20 0.34
LMNA P02545 2/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
KCNH3 Q9ULD8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17963227 0.77 CTSA (0.43) ALDH1A1MAPK1GRM5MAPTLMNA
SCHEMBL3097555 0.76 MAPK1 (0.47) ALDH1A1MAPK1CYP2C9MAPTKDM4E
SCHEMBL1180045 0.76 MAPK1 (0.47) ALDH1A1MAPK1MAPTKDM4EKMT2A
SCHEMBL3087925 0.76 RAB9A (0.48) ALDH1A1MAPK1KDM4EMEN1KMT2A
SCHEMBL3094255 0.75 MAPK1 (0.59) ALDH1A1MAPK1MAPTKDM4EKMT2A
SCHEMBL3079926 0.74 MAPK1 (0.40) ALDH1A1MAPK1CYP2C9MAPTKDM4E
SCHEMBL12410776 0.70 LMNA (0.52) ALDH1A1MAPK1MAPTKDM4EMEN1
SCHEMBL5200407 0.69 KDM4E (0.41) ALDH1A1GRM5KDM4E
SCHEMBL3558150 0.69 CD38 (0.47) CYP1A2CYP2C19
SCHEMBL3739438 0.68 P2RX7 (0.68) ALDH1A1GRM5CYP2C9MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2217594-B1 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2014-01-08 EP disclosed
US-8299086-B2 Pyrimidine derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-30 US disclosed
US-20100234346-A1 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-16 US disclosed
EP-2217594-A2 NOVEL PYRIMIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-08-18 EP disclosed
WO-2009057079-A2 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234346-A1 NOVEL PYRIMIDINE DERIVATIVES TYMP, TYMS, DPYD ALDH1A1 680/4885MAPK1 2392/4885GRM5 3873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.